GPGrossPatternRESEARCH SYSTEM
SEC CHECK OPERATIONAL
GROSSPATTERN / FUNDAMENTAL STATE / POINT IN TIME

ALNY · Sep 30, 2026

ALNYLAM PHARMACEUTICALS, INC.. A multidimensional configuration derived from the filing available at this observation—never a composite score or recommendation.

STATE CAPABILITYLEVEL 4[email protected]
Inspectable configuration

State dimensions

Filing0001178670-26-000076General Corporate
Capex intensity55thOwn-history percentile · N=20
Evidence method

Level · gp.fundamentals.capex_revenue_ratio

4.79% · OPTIONAL · VALID

Operating cash generation90thOwn-history percentile · N=20
Evidence method

Ratio · gp.fundamentals.operating_cash_flow + gp.fundamentals.revenue

23.39% · OPTIONAL · VALID

Revenue growth10thOwn-history percentile · N=20
Evidence method

Yoy · gp.fundamentals.revenue

16.74% · CORE · VALID

Inventory pressure20thOwn-history percentile · N=20
Evidence method

Level · gp.fundamentals.inventory_revenue_ratio

7.26% · OPTIONAL · VALID

Gross margin0thOwn-history percentile · N=20
Evidence method

Level · gp.fundamentals.gross_margin

75.19% · CORE · VALID

Operating margin90thOwn-history percentile · N=20
Evidence method

Level · gp.fundamentals.operating_margin

23.72% · CORE · VALID

R&D intensity0thOwn-history percentile · N=20
Evidence method

Ratio · gp.fundamentals.rnd + gp.fundamentals.revenue

28.02% · OPTIONAL · VALID

SBC intensity0thOwn-history percentile · N=20
Evidence method

Level · gp.fundamentals.sbc_revenue_ratio

5.43% · OPTIONAL · VALID

As-filed lineage

Fundamental state history

Each observation is tied to the filing and facts available at that report date. Amendments remain separate.

History17 statesSelf-history eligible
Sep 30, 20180/7 normalizedLevel 3Dec 31, 20180/7 normalizedLevel 3Mar 31, 20190/7 normalizedLevel 3Jun 30, 20190/8 normalizedLevel 3Sep 30, 20190/8 normalizedLevel 3Dec 31, 20190/8 normalizedLevel 3Mar 31, 20200/8 normalizedLevel 3Jun 30, 20204/8 normalizedLevel 3Sep 30, 20207/8 normalizedLevel 3Dec 31, 20207/8 normalizedLevel 3Dec 31, 20218/8 normalizedLevel 3Sep 30, 20228/8 normalizedLevel 3Dec 31, 20228/8 normalizedLevel 3Mar 31, 20238/8 normalizedLevel 3Jun 30, 20238/8 normalizedLevel 3Sep 30, 20238/8 normalizedLevel 3Sep 30, 20268/8 normalizedLevel 4
Period transition

What moved in the state?

Growth Decreased
Previous
66.86%
Current
16.74%
Delta
-50.12%
Inventory Pressure Decreased
Previous
7.52%
Current
7.26%
Delta
-0.26%
Margin Decreased
Previous
76.90%
Current
75.19%
Delta
-1.71%
Profitability Increased
Previous
17.93%
Current
23.72%
Delta
5.79%
R And D Intensity Decreased
Previous
32.00%
Current
28.02%
Delta
-3.98%
Sbc Intensity Decreased
Previous
6.71%
Current
5.43%
Delta
-1.28%
Self-history only

Previous similar states

Similarity compares compatible valid dimensions from this issuer's own point-in-time history. No market-return claim is attached.

Sep 30, 2021
Similarity
83%
Compared
8 dimensions
Coverage
100%
Growth 10.0 · Margin 25.0 · Profitability 2.3 · Sbc Intensity 7.7 · Capex Intensity 31.9 · Cash Generation 6.7 · R And D Intensity 7.7 · Inventory Pressure 21.7
Jun 30, 2022
Similarity
79%
Compared
8 dimensions
Coverage
100%
Growth 10.0 · Margin 20.0 · Profitability 8.8 · Sbc Intensity 0.0 · Capex Intensity 48.8 · Cash Generation 3.3 · R And D Intensity 12.5 · Inventory Pressure 20.0
Sep 30, 2024
Similarity
79%
Compared
8 dimensions
Coverage
100%
Growth 10.0 · Margin 15.0 · Profitability 5.0 · Sbc Intensity 5.0 · Capex Intensity 55.0 · Cash Generation 0.0 · R And D Intensity 15.0 · Inventory Pressure 5.0
Dec 31, 2020
Similarity
78%
Compared
7 dimensions
Coverage
88%
Margin 22.2 · Profitability 10.0 · Sbc Intensity 0.0 · Capex Intensity 45.0 · Cash Generation 12.2 · R And D Intensity 10.0 · Inventory Pressure 20.0
Jun 30, 2025
Similarity
78%
Compared
8 dimensions
Coverage
100%
Growth 0.0 · Margin 10.0 · Profitability 5.0 · Sbc Intensity 50.0 · Capex Intensity 35.0 · Cash Generation 5.0 · R And D Intensity 5.0 · Inventory Pressure 10.0
Research Graph

Related governed research

Analogous To · ALNY state analogue 2 →Analogous To · ALNY state analogue 4 →Analogous To · ALNY state analogue 3 →Analogous To · ALNY state analogue 1 →Compared To · Pharmaceutical Preparations peers →Analogous To · ALNY state analogue 5 →Derived From · ALNY Company Quality Vector →Has State · ALNYLAM PHARMACEUTICALS, INC. →Transitioned To · ALNY GROWTH_DECREASED →Transitioned To · ALNY INVENTORY_PRESSURE_DECREASED →Transitioned To · ALNY MARGIN_DECREASED →Transitioned To · ALNY PROFITABILITY_INCREASED →

Method Percentiles and historical matches use only observations available at each point in time. Missing dimensions remain missing. Public price outcomes and cross-market analogues are deliberately absent.